SERPINA1 and alpha 1-antitrypsin deficiency: Overall, we found that alpha-1-antitrypsin (A1AT) deficiency was present in 10.8% of patients with biliary tract cancer (BTC), a higher rate than the general population, and seemed to be associated with specific clinicopathological features.